Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innophos is an active specialty ingredients manufacturer focused on phosphates, chelated minerals, and formulation solutions serving food, health and nutrition, pharmaceutical, oral care, and industrial markets. In healthcare-related markets, the company primarily supplies pharmaceutical excipients and nutrition ingredients rather than developing therapeutic drug candidates. Its pharma portfolio includes calcium phosphate excipients and co-processed multifunctional excipients marketed for tablets, capsules, gummies, premixes, and nutritional beverages. Innophos operates a manufacturing-led business with multiple plants across North America and Asia and emphasizes supply reliability, quality systems, and GMP-aligned production for excipient applications. Historically public as Innophos Holdings, Inc. under NASDAQ ticker IPHS, the company was taken private in 2020 by One Rock Capital Partners with Farol Asset Management.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Innophous Holdings.